Systemic sclerosis & Raynaud's
Prevention and management of gastrointestinal side effects in patients with systemic sclerosis-interstitial lung disease receiving anti-fibrotic therapy: a modified Delphi consensus study
Methodological detailstwo online rounds, agreement threshold of at least two-thirds of panellists, Two online rounds, April–September 2024
- Two online rounds
- Agreement threshold of at least two-thirds of panellists
- Two online rounds, April–September 2024
Recommendations
As issued by the authors
- 100% agreement
Preliminary evaluation of gastrointestinal (GI) status in patients with SSc-ILD undergoing anti-fibrotic therapy
- 100%
Take into account pre-existing diarrhoea
- 95%
Take into account weight loss
- 100%
Take into account nausea/loss of appetite
Definition of specific tests and exams for these conditions
- 100%
Inform patients on potential GI complications
- 85%
Nutritional preventive advice
- 100%
Monitor GI status during anti-fibrotic therapy
- 75%
Monitoring at 3-month intervals
- 95%
Dose-reduction of anti-fibrotic therapy and, if needed, temporary discontinuation in presence of diarrhoea
- 85%
Dose-reduction and, if needed, temporary discontinuation in presence of weight loss
- 90%
In presence of nausea or loss of appetite, dose-reduction, with no immediate need for drug discontinuation
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →